Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Conference News VIVA 2024

Advocates Urge Heat Maps and Grassroots Campaigns to Improve PAD Care

L.A. McKeown

November 07, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News VIVA 2023

‘Dire’ Lack of Vascular Care in Underserved Areas Needs Creativity, Compassion

L.A. McKeown

November 03, 2023

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

L.A. McKeown

November 04, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News VIVA 2021

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

L.A. McKeown

October 07, 2021

News Conference News VIVA 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

L.A. McKeown

October 06, 2021

News Conference News VIVA 2020

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

L.A. McKeown

November 27, 2020

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

L.A. McKeown

November 09, 2020

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

L.A. McKeown

November 13, 2019

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

Presentation VIVA 2017

Paclitaxel-Eluting Stent Treatment for PAD: Insights from the Zilver PTX Post-Market Study in Japan

Presenter: Michael Dake

September 14, 2017

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

Advertisement

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

Advocates Urge Heat Maps and Grassroots Campaigns to Improve PAD Care

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

‘Dire’ Lack of Vascular Care in Underserved Areas Needs Creativity, Compassion

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

Paclitaxel-Eluting Stent Treatment for PAD: Insights from the Zilver PTX Post-Market Study in Japan

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content